Plasma sarcosine measured by gas chromatography-mass spectrometry distinguishes prostatic intraepithelial neoplasia and prostate cancer from benign prostate hyperplasia
Artículo
![Thumbnail](/themes/Mirage2/images/cubierta.jpg)
Open/ Download
Access note
Acceso Abierto
Publication date
2020Metadata
Show full item record
Cómo citar
Markin, Pavel A.
Cómo citar
Plasma sarcosine measured by gas chromatography-mass spectrometry distinguishes prostatic intraepithelial neoplasia and prostate cancer from benign prostate hyperplasia
Author
Abstract
Objective: Sarcosine was postulated in 2009 as a biomarker for prostate cancer (PCa). Here, we assess plasma sarcosine as a biomarker that is complementary to prostate-specific antigen (PSA).
Methods: Plasma sarcosine was measured using gas chromatographymass spectrometry (GC-MS) in adults classified as noncancerous controls (with benign prostate hyperplasia [BPH], n = 36), with prostatic intraepithelial neoplasia (PIN, n = 16), or with PCa (n = 27). Diagnostic accuracy was assessed using receiver operating characteristic curve analysis.
Results: Plasma sarcosine levels were higher in the PCa (2.0 mu M [1.3-3.3 mu M], P <.01) and the PIN (1.9 mu M [1.2-6.5 mu M], P <.001) groups than in the BPH (0.9 mu M [0.6-1.4 mu M]) group. Plasma sarcosine had "good" and "very good" discriminative capability to detect PIN (area under the curve [AUC], 0.734) and PCa (AUC, 0.833) versus BPH, respectively. The use of PSA and sarcosine together improved the overall diagnostic accuracy to detect PIN and PCa versus BPH.
Conclusion: Plasma sarcosine measured by GC-MS had "good" and "very good" classification performance for distinguishing PIN and PCa, respectively, relative to noncancerous patients diagnosed with BPH.
Patrocinador
Project 5-100 Sechenov University Grant
Indexation
Artículo de publicación ISI Artículo de publicación SCOPUS
Quote Item
Laboratory Medicine 2020;51:566-573
Collections
The following license files are associated with this item:
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Chile
Related items
Showing items related by title, author, creator and subject.
-
Khauli, Raja; Ferrigno, Robson; Guimarães, Gustavo; Bulbulan, Muhammad; Serrano Uson, Pedro Luis Junior; Salvajoli, Bernardo; Freitas Palhares, Daniel Moore; Racy, Douglas; Gil, Erlon; Freire de Arruda, Fernando; Caserta Lemos, Gustavo; Carvalhal, Gustavo Franco; de Carvalho, Icaro Thiago; Fernandes Martins, Igor Agustín; Pinto Gimpel, Iván Frederico; Salvajoli, João Víctor; Chambo, José Luis; Pontes, José; Ribeiro Filho, Leopoldo Alves; Nogueira, Lucas; Pereira Freitas, Marcelo Roberto; Wroclawski, Marcelo; Arap, Marco Antonio; Sadi, Marcus Vinicius; Coelho, Rafael; Gadia, Rafael; Ledezma Rojas, Rodrigo Antonio; Moraes Hanriot, Rodrigo de; Baroni, Ronaldo; Zequi, Stenio; Nahas, William Carlos; Alfer, Wladimir; Cotait Maluf, Fernando (Lippincott Williams & Wilkins, 2021)PURPOSE To generate and present survey results on important issues relevant to treatment and follow-up of localized and locally advanced, high-risk prostate cancer (PCa) focusing on developing countries. METHODS A panel ...
-
Monteiro, Fernando S. M.; Schutz, Fabio A.; Morbeck P., Igor A.; Bastos, Diogo A.; De Padua, Fernando V.; Costa, Leonardo A. G. A.; Maia, Manuel C.; Rinck Jr., José A.; Zequi, Stenio de Cassio; Da Trindade, Karine M.; Alfer Jr., Wladimir; Nahas, William C.; Dos Santos, Lucas V.; Ferrigno, Robson; Da Rosa, Diogo A. R.; Sade, Juan P.; Orlandi Jorquera, Francisco Javier; De Oliveira, Fernando N. G.; Soares, Andrey (Lippincott Williams & Wilkins, 2021)PURPOSE To present a summary of the treatment and follow-up recommendations for the biochemical recurrence in castration-sensitive prostate cancer (PCa) acquired through a questionnaire administered to 99 PCa experts ...
-
De Almeida Luz, Murilo; Cardoso Guimarães, Gustavo; Nardi, Aguinaldo César; Feres Lima Pompeo, Alexandre Saad; Sadek Sarkis, Álvaro; Nowier, Amr; Lima Pompeo, Antonio Carlos; Nardozza Jr, Archimedes; Adamy Jr, Ari; Carneiro, Arie; Peres Salvajoli, Bernardo; Benigno, Bruno Santos; De Freitas Jr, Celso Heitor; Daher Cezar Chade, Clarissa Angotti; Freitas Palhares, Daniel Moore; Citarella Otero, Danilo Armando; Vieira da Silva Neto, Deusdedit Cortéz; Carvalhal, Eduardo Franco; Gil, Erlon; De Arruda, Fernando Freire; Korkes, Fernando; Lemos, Gustavo Caserta; Carvalhal, Gustavo Franco; De Carvalho, Icaro Thiago; Pinto Gimpel, Iván Federico; Chambô, José Luis; Pontes Jr, José; Ribeiro Filho, Leopoldo Alves; Nogueira, Lucas Mendes; Wroclawski, Marcelo Langer; Pereira Freitas, Marcelo Roberto; Arap, Marco Antônio; Sadi, Marcus Vinícius; Bulbul, Muhammad; Coelho, Rafael Ferreira; Gadia, Rafael; Khauli, Raja B.; Dos Reis, Rodolfo Borges; Ledezma Rojas, Rodrigo Antonio; Guimarães, Roger Guilherme; Aldousari, Saad; Ferrigno, Robson (Lippincott Williams & Wilkins, 2021)PURPOSE A group of international urology and medical oncology experts developed and completed a survey on prostate cancer (PCa) in developing countries. The results are reviewed and summarized, and recommendations on ...